Filtered By:
Drug: Activase

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 1186 results found since Jan 2013.

Acute Ischemic Stroke
This article discusses the pathophysiology underlying the various types of ischemic stroke; the risk factors for ischemic stroke; stroke presentation; and the evidence-based treatments, nursing assessments, and monitoring protocols that are critical to patient recovery.PMID:34402461 | DOI:10.1097/01.NAJ.0000790184.66496.1d
Source: The American Journal of Nursing - August 17, 2021 Category: Nursing Authors: Nneka Lotea Ifejika Heather H Washington Kimberly R Glaser Source Type: research

CE: Acute Ischemic Stroke
This article discusses the pathophysiology underlying the various types of ischemic stroke; the risk factors for ischemic stroke; stroke presentation; and the evidence-based treatments, nursing assessments, and monitoring protocols that are critical to patient recovery.PMID:34402461 | DOI:10.1097/01.NAJ.0000790184.66496.1d
Source: The American Journal of Nursing - August 17, 2021 Category: Nursing Authors: Nneka Lotea Ifejika Heather H Washington Kimberly R Glaser Source Type: research

Emerging agents for the treatment and prevention of stroke: progress in clinical trials
Expert Opin Investig Drugs. 2021 Sep 24. doi: 10.1080/13543784.2021.1985463. Online ahead of print.ABSTRACTINTRODUCTION: Recent years have witnessed unprecedented progress in stroke care, but unmet needs persist regarding the efficacy of acute treatment and secondary prevention. Novel approaches are being tested to enhance the efficacy of thrombolysis or provide neuroprotection in non-thrombolized patients.AREAS COVERED: The current review highlights pharmaceutical agents under evaluation in clinical trials concerning the acute, subacute, and chronic phase post-stroke. We examine the evidence in favor of tenecteplase as an...
Source: Expert Opinion on Investigational Drugs - September 24, 2021 Category: Drugs & Pharmacology Authors: Apostolos Safouris Georgios Magoufis Georgios Tsivgoulis Source Type: research

Treatments in Ischemic Stroke: Current and Future
Background and Aim: Despite progress made over the last 30 years, stroke is still a leading cause of disability and mortality; likewise, its burden is expected to increase over the next decades, due to population growth and aging. The development of drugs with better safety-efficacy profiles as well as strategies able to improve ischemic stroke management from the pre-hospital setting is needed.Summary: The pathophysiology of ischemic stroke involves multiple pathways resulting in cerebral artery obstruction and brain tissue ischemia. To date, the only approved drug for acute ischemic stroke is intravenous thrombolytic alt...
Source: European Neurology - August 2, 2022 Category: Neurology Source Type: research

Thrombolytic Agents for Acute Ischaemic Stroke Treatment: the Past, Present and Future.
Abstract Despite advances in the diagnosis and treatment of acute ischaemic stroke in the past two decades, stroke has remained the third cause of mortality and the single leading cause of disability worldwide. The immediate goal of acute ischaemic stroke therapy is to salvage the ischaemic penumbra through recanalisation of the occluded cerebral blood vessel. This is currently achieved through thrombolytics, which are pharmacological agents that can break up a clot blocking the flow of blood. To date, the only approved thrombolytic for treatment of acute ischaemic stroke is recombinant tissue plasminogen activato...
Source: CNS and Neurological Disorders Drug Targets - February 4, 2013 Category: Drugs & Pharmacology Authors: Balami JS, Chen R, Sutherland BA, Buchan AM Tags: CNS Neurol Disord Drug Targets Source Type: research

The efficacy and safety of intravenous thrombolysis with alteplase in the treatment of ischaemic stroke in a rural hospital.
Conclusions: The indications for intravenous thrombolysis in patients with IS should be strictly analysed so that the treatment is effective and safe especially in older patients, patients with greater severity of neurological symptoms and patients with old post-stroke lesions in baseline CT. PMID: 23986420 [PubMed - as supplied by publisher]
Source: Neurologia i Neurochirurgia Polska - September 3, 2013 Category: Neurology Authors: Sobolewski P, Sledzińska-Dźwigał M, Szczuchniak W, Hatalska-Żerebiec R, Grzesik M, Sobota A Tags: Neurol Neurochir Pol Source Type: research

Routine serum C‐reactive protein and stroke outcome after intravenous thrombolysis
ConclusionsAccording to our findings, elevated routine serum CRP measured within 24 h after admission does not seem to independently affect the outcome in patients receiving intravenous thrombolysis for stroke. However, further studies of blood samples taken directly before the treatment are needed.
Source: Acta Neurologica Scandinavica - February 20, 2014 Category: Neurology Authors: M. Karlinski, J. Bembenek, K. Grabska, A. Kobayashi, A. Baranowska, T. Litwin, A. Czlonkowska Tags: Original Article Source Type: research